Found 1 Presentation For Request "1391p"
1391P - Capmatinib vs docetaxel as second- or third-line (2/3L) therapy in patients (pts) with METex14-mutated advanced NSCLC (aNSCLC): The GeoMETry-III trial
- Oscar Jose Juan Vidal (Valencia, Spain)
Abstract
Background
Capmatinib (cap), a selective MET inhibitor, is approved by multiple health authorities worldwide, including US, Japan, and EU, in
Methods
GeoMETry-III is a multicenter, open-label, randomized, phase 3 trial (NCT04427072). Eligible pts included
Results
As of Feb 15, 2023, data cutoff, 22 pts were randomized 2:1 to cap (n = 15) or doc (n = 7) arms. Baseline characteristics were generally comparable between arms. The observed benefit with cap vs doc in median PFS was not statistically significant: 6.1 months vs 4.1 months; HR, 0.46; 95% CI 0.16-1.3;
Conclusions
Overall, the numerical differences in PFS and ORR showed trends favoring cap, and together with safety, are consistent with previous results of the pivotal GeoMETry mono-1 study. The GeoMETry-III trial was terminated early due to enrollment constraints.
Clinical trial identification
NCT04427072.
Editorial acknowledgement
Medical writing support for this abstract was provided by Apra Manral, Novartis Healthcare Pvt. Ltd.
Legal entity responsible for the study
Novartis.
Funding
Novartis.
Disclosure
O.J. Juan Vidal: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Merck Sharp & Dohme, Lilly, Takeda, AstraZeneca, Janssen; Financial Interests, Personal, Invited Speaker: Roche/Genentech; Financial Interests, Institutional, Funding: AstraZeneca. M.K. Singhal: Financial Interests, Personal, Research Grant, Investigator grant: Novartis, Roche, Pfizer; Financial Interests, Personal, Other, Honorarium: Novartis, Roche, Pfizer, Emcure, MSD, AstraZeneca, Dr Reddys, Intas; Financial Interests, Personal, Other, Travel grant: Dr Reddys Lab, Pfizer, Merck; Financial Interests, Personal, Speaker, Consultant, Advisor: Zydus, Axiom, Lupin. R.M. Alvarez: Financial Interests, Personal, Invited Speaker: PharmaMar; Financial Interests, Personal, Advisory Board: Boehringer, Novartis, Roche; Financial Interests, Personal, Other, conference registration: MSD Oncology; Financial Interests, Institutional, Coordinating PI: Roche; Financial Interests, Personal and Institutional, Coordinating PI: Janssen Oncology, Rain Therapeutics, Boehringer, Cebiotex, Novartis. P. Souquet: Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Research Funding: Novartis; Financial Interests, Personal, Other, Honoraria: Novartis. S. Kim: Financial Interests, Personal, Advisory Role: AstraZeneca, Novartis, Amgen, Eli Lilly, Boehringer Ingelheim; Financial Interests, Personal and Institutional, Research Funding: AstraZeneca, Novartis; Financial Interests, Personal, Other, Honoraria: Boehringer Ingelheim. A. Robeva, A. Jary, M. Miskic: Financial Interests, Personal, Full or part-time Employment: Novartis. S. Glaser: Financial Interests, Personal, Full or part-time Employment: Novartis; Financial Interests, Personal, Stocks/Shares: Novartis, Alcon.. J. Wolf: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Blueprint, BMS, Boehringer Ingelheim, Daiichi Sankyo, Ignyta, Janssen, Lilly, Loxo, MSD, Novartis, Pfizer, Roche, Seattle Genetics, Takeda; Financial Interests, Personal, Invited Speaker: Bayer, Chugai; Financial Interests, Institutional, Research Grant: BMS, Janssen, Novartis, Pfizer. All other authors have declared no conflicts of interest.